DE212011100195U1 - Antikörper, der das Tumorwachstum stoppt oder verzögert (Varianten) - Google Patents

Antikörper, der das Tumorwachstum stoppt oder verzögert (Varianten) Download PDF

Info

Publication number
DE212011100195U1
DE212011100195U1 DE212011100195U DE212011100195U DE212011100195U1 DE 212011100195 U1 DE212011100195 U1 DE 212011100195U1 DE 212011100195 U DE212011100195 U DE 212011100195U DE 212011100195 U DE212011100195 U DE 212011100195U DE 212011100195 U1 DE212011100195 U1 DE 212011100195U1
Authority
DE
Germany
Prior art keywords
fgfr1
monoclonal antibody
growth factor
cells
fgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE212011100195U
Other languages
German (de)
English (en)
Other versions
DE212011100195U9 (de
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OBSHESTVO S OGRANICHENNOY OTVETSTVENNOSTIU "ONCOMAX"
OBSHESTVO S OGRANICHENNOY OTVETSTVENNOSTIU ONCOMAX
Original Assignee
OBSHESTVO S OGRANICHENNOY OTVETSTVENNOSTIU "ONCOMAX"
OBSHESTVO S OGRANICHENNOY OTVETSTVENNOSTIU ONCOMAX
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OBSHESTVO S OGRANICHENNOY OTVETSTVENNOSTIU "ONCOMAX", OBSHESTVO S OGRANICHENNOY OTVETSTVENNOSTIU ONCOMAX filed Critical OBSHESTVO S OGRANICHENNOY OTVETSTVENNOSTIU "ONCOMAX"
Publication of DE212011100195U1 publication Critical patent/DE212011100195U1/de
Publication of DE212011100195U9 publication Critical patent/DE212011100195U9/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE212011100195U 2011-02-07 2011-03-30 Antikörper, der das Tumorwachstum stoppt oder verzögert (Varianten) Expired - Lifetime DE212011100195U1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2011104017 2011-02-07
RU2011104017/10A RU2440142C1 (ru) 2011-02-07 2011-02-07 Антитело, останавливающее или замедляющее рост опухоли (варианты), способ подавления роста опухоли, способ диагностики злокачественных образований
PCT/RU2011/000200 WO2012108782A1 (ru) 2011-02-07 2011-03-30 Антитело, останавливающее или замедляющее рост опухоли (варианты)

Publications (2)

Publication Number Publication Date
DE212011100195U1 true DE212011100195U1 (de) 2013-12-17
DE212011100195U9 DE212011100195U9 (de) 2014-06-26

Family

ID=45785607

Family Applications (1)

Application Number Title Priority Date Filing Date
DE212011100195U Expired - Lifetime DE212011100195U1 (de) 2011-02-07 2011-03-30 Antikörper, der das Tumorwachstum stoppt oder verzögert (Varianten)

Country Status (4)

Country Link
US (1) US20140105821A1 (ru)
DE (1) DE212011100195U1 (ru)
RU (1) RU2440142C1 (ru)
WO (1) WO2012108782A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2530762C2 (ru) * 2012-12-14 2014-10-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ диагностики мультиформной глиобластомы с помощью мрт
WO2015066452A2 (en) * 2013-11-01 2015-05-07 Foundation Medicine, Inc. Methods of treating pediatric cancers
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
RU2634573C1 (ru) * 2016-07-05 2017-10-31 государственное бюджетное образовательное учреждение высшего профессионального образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ стратификации риска поражения сердечно-сосудистой системы у пациентов с хронической болезнью почек
WO2018095932A1 (en) * 2016-11-22 2018-05-31 Merck Patent Gmbh Monoclonal antibody directed to fgfr1
EP3544998A1 (en) * 2016-11-22 2019-10-02 Merck Patent GmbH Monoclonal antibody directed to fgfr1

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO2005037235A2 (en) * 2003-10-16 2005-04-28 Imclone Systems Incorporated Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
US20090022716A1 (en) 2001-03-02 2009-01-22 Imclone Systems Inc. Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US7498416B2 (en) * 2001-06-20 2009-03-03 Fibron Limited Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
EP1910542B1 (en) * 2005-07-22 2009-12-02 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2667019C (en) * 2006-10-27 2016-03-29 Genentech, Inc. Antibodies and immunoconjugates and uses therefor

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US20090022716A1 (en) 2001-03-02 2009-01-22 Imclone Systems Inc. Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US7498416B2 (en) * 2001-06-20 2009-03-03 Fibron Limited Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
WO2005037235A2 (en) * 2003-10-16 2005-04-28 Imclone Systems Incorporated Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
EP1910542B1 (en) * 2005-07-22 2009-12-02 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins

Non-Patent Citations (37)

* Cited by examiner, † Cited by third party
Title
B. Brodeur, P. Tsang Monoclonal Antibpdy Production Techniques and Application, pp. 51-62 (Marcel Dekker Inc., New York, 1987)
C. Behrens et al. J Clinical cancer research 14, 19 (2008)
D Johnson, L. Williams, J Adv. Cancer Res., 60, 1 (1993)
D. Kozbor et al. Immunol. 133, 3001 (1984)
David et al. (J Biochemistry 13, 1014 (1974)
E. Devilard et al. J BMC Cancer 6, 272 (2006)
E. Shin et al. J Cancer Res Clin Oncol. 126, 9 (2000)
Epstein et al. beschrieben wurde (Proc. Nat. Acad. Sci. 82, 3688 (1985)
Fibroblast growth factor - Wikipedia, the free encyclopedia *
G. Köhler, C. Milstein. J Nature 256, 495 (1975)
G. Lefevre et al. J Investigative Ophthalmology and Visual Science 50 (2009)
H. Armelin. PNAS 70,9 (1973)
Hanter et al. (J Nature 144, 945 (1962)
Huang et al. (Proc. Nat. Acad. Sci. 77, 4030 (1980)
I. Tsimafeyeu et al. ESMO-ECCO 09 (2009): Tabelle 1
I. Tsimafeyeu et al. Experimental & Clinical Cancer Research, 28, 30 (2009)
I. Tsimafeyeu et al. J. Clin. Oncology 25, 18S (2007)
I. V. Tymofeev et al. Russische onkologische Zeitschrift, Nr. 5 (2008)
J. Folkman et al. Nature; 339, 58 (1989)
J. Goding. Monoclonal Antibodies: Pronciples arid Practice, pp. 59-103 (Academic Press, 1986)
J. Golding. Monoclonal Antibodies: Principles and Practice, pp. 59-10 (Academic Press, 1986)
K. Freier J Oral Oncology 43, 1 (2007)
K. Sigiura et al. J Oncology reports 17, 3 (2007)
Langer (Chem. Rech. 12 (1982)
Langer et al. (J Biomed. Mater Res. 15, 167 (1981)
M. Koziczak et al. J Oncogene, 23, 20 (2004)
McKeehan et al. J Prog Nucleic Acid Res. Mol. Biol., 59, 135 (1998)
N. Ferrara et al. Proc. Nat. Acad. Sci 84: 5773 (1987)
N. Weidner et al. New Eng. J. Med., 324: 1 (1991)
Nigren (J. Histochem. and Cytochem. 30, 407 (1982)
P. Carter et al. J Biotechnology 10, 163 (1992)
P. Carter et al. Proc. Nat. Acad. Sci. 89, 4285 (1992)
P. Munson, D. Rodbard, J Anal. Biochem. 107, 220 (1980)
Payne et al (J Immunol. Meth. 40, 219 (1981)
S. Morrison et al. Proc. Nat. Acad. Sci. 81, 6851 (1984)
Sidman et al. (Biopolymers 22, 547 (1983)
Yelton u. a. (J Curr. Top. Microbiol. Immunol. 81, 1 (1978)

Also Published As

Publication number Publication date
RU2440142C1 (ru) 2012-01-20
US20140105821A1 (en) 2014-04-17
DE212011100195U9 (de) 2014-06-26
WO2012108782A1 (ru) 2012-08-16

Similar Documents

Publication Publication Date Title
DE69232539T2 (de) Verwendung von anti-VEGF Antikörpern zur Behandlung von Krebs
Xie et al. Early blockade of injured primary sensory afferents reduces glial cell activation in two rat neuropathic pain models
DE60128208T2 (de) Verfahren zum Behandeln von Krebs mit Anti-Neurotrophin-Mitteln
DE69634079T2 (de) Antagoniste des vasculären endothelzellewachstumfaktors
DE69926536T2 (de) Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
DE69032662T2 (de) Verfahren und zusammensetzungen zur verbesserung der symptome von sepsis
FI120721B (fi) IL-6-antagonistin käyttö farmaseuttisen koostumuksen valmistamiseksi nivelreuman hoitamiseksi
DE60027768T2 (de) Behandlung von metastatischer krankheit
RU2322261C2 (ru) Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
Quan et al. Development of a macromolecular prodrug for the treatment of inflammatory arthritis: mechanisms involved in arthrotropism and sustained therapeutic efficacy
DE212011100195U1 (de) Antikörper, der das Tumorwachstum stoppt oder verzögert (Varianten)
US20060171946A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
DE69528624T2 (de) Anti-Fas Antikörper gegen rheumatische Krankheiten
DE60223688T2 (de) Verfahren zur behandlung von multiplem myelom
DE60003152T2 (de) Tumor nekrose faktor antagonisten und ihre verwendung gegen endometriose
AU2009205428B2 (en) Inhibiting angiogenesis using EGFL8 antagonists
Del Moral et al. Chronic cyclosporin A nephrotoxicity, P-glycoprotein overexpression, and relationships with intrarenal angiotensin II deposits.
EP2450055B1 (en) Method for suppressing renal tumor growth by blocking fibroblast growth factor receptor
DE112012000439T5 (de) Stammzellfaktor-Inhibitor
EP3146062B1 (en) Use of ginsenoside m1 for inhibiting renal fibrosis
DE60312684T2 (de) Plazenta-wachstumsfaktor als target für die behandlung von osteoporose
JP2003504379A (ja) 線維芽細胞増殖因子の抗イディオタイプ抗体及びそれらの薬剤としての使用
Sabuncuoğlu et al. Attenuation of postlaminectomy epidural fibrosis with monoclonal antibodies against intercellular adhesion molecule-1 and CD-18
DE69626510T2 (de) Verwendung des leukämie-inhibitor-faktor und endothelin antagonisten
Foster et al. Genetic or Pharmacological Ablation of Acid-Sensing Ion Channel 1a (ASIC1a) Is Not Neuroprotective in a Mouse Model of Spinal Cord Injury

Legal Events

Date Code Title Description
R150 Utility model maintained after payment of first maintenance fee after three years
R207 Utility model specification

Effective date: 20140206

R150 Utility model maintained after payment of first maintenance fee after three years

Effective date: 20140203

R163 Identified publications notified
R163 Identified publications notified

Effective date: 20140326

R082 Change of representative

Representative=s name: V. FUENER EBBINGHAUS FINCK HANO, DE

R151 Utility model maintained after payment of second maintenance fee after six years
R152 Utility model maintained after payment of third maintenance fee after eight years
R071 Expiry of right